In breast cancer clinical samples, PDE5 overexpression was validated by RT-PCR and immunohistochemistry assays, and was associated with important clinical parameters, such as tumor grading, stage, lymph node positivity, and poor prognosis [11,13,14]. Here, PDE5A is linked to neoplasm.